Image 1
Capecitabine Tablet, Film Coated
Product Images NDC 0093-7473
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 0093-7473). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
Image 3
Image 4
Image 5
This is a comparison of two chemotherapy regimens for cancer treatment: 5-Fluorouracil (5-FU) combined with Leucovorin (Mayo Regimen) and Capecitabine. The dosage for Capecitabine is 1250 mg/sqm, to be taken twice daily in intervals. The chart shows the dosage in milligrams over time in days.*
Image 6
Image 7
The text appears to be a table that includes estimated probabilities for Docetaxel and Capecitabine medication dosages. The dosages are listed in mg/sqm/3 weeks and mg/sqm twice daily, respectively, and are shown in relation to their corresponding probability value. Time is also mentioned in days, but it is unclear how it is related to the medication dosages and probability.*
Image 8
Image 9
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
